Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:1372:119-143.
doi: 10.1007/978-981-19-0394-6_9.

Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment

Affiliations

Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment

Xiaoyue Pan. Adv Exp Med Biol. 2022.

Abstract

High plasma levels of lipids and/or lipoproteins are risk factors for atherosclerosis, nonalcoholic fatty liver disease (NAFLD), obesity, and diabetes. These four conditions have also been identified as risk factors leading to the development of chronic kidney disease (CKD). Although many pathways that generate high plasma levels of these factors have been identified, most clinical and physiologic dysfunction results from aberrant assembly and secretion of lipoproteins. The results of several published studies suggest that elevated levels of low-density lipoprotein (LDL)-cholesterol are a risk factor for atherosclerosis, myocardial infarction, coronary artery calcification associated with type 2 diabetes, and NAFLD. Cholesterol metabolism has also been identified as an important pathway contributing to the development of CKD; clinical treatments designed to alter various steps of the cholesterol synthesis and metabolism pathway are currently under study. Cholesterol synthesis and catabolism contribute to a multistep process with pathways that are regulated at the cellular level in renal tissue. Cholesterol metabolism may also be regulated by the balance between the influx and efflux of cholesterol molecules that are capable of crossing the membrane of renal proximal tubular epithelial cells and podocytes. Cellular accumulation of cholesterol can result in lipotoxicity and ultimately kidney dysfunction and failure. Thus, further research focused on cholesterol metabolism pathways will be necessary to improve our understanding of the impact of cholesterol restriction, which is currently a primary intervention recommended for patients with dyslipidemia.

Keywords: Apolipoprotein; Cholesterol accumulation; Cholesterol metabolism; Chronic kidney disease; Lipotoxicity.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Several behavioral, clinical disease and genetic factors contributing to cholesterol-related CKD and nephrotic syndrome according to the published data from several groups.

Similar articles

Cited by

References

    1. (1997). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349, 1857–1863. - PubMed
    1. Afsar B, Yilmaz MI, Siriopol D, Unal HU, Saglam M, Karaman M, Gezer M, Sonmez A, Eyileten T, Aydin I, et al. (2017). Thyroid function and cardiovascular events in chronic kidney disease patients. J Nephrol 30, 235–242. - PubMed
    1. Agrawal S, He JC, and Tharaux PL (2021). Nuclear receptors in podocyte biology and glomerular disease. Nat Rev Nephrol 17, 185–204. - PubMed
    1. Agrawal S, Zaritsky JJ, Fornoni A, and Smoyer WE (2017). Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14, 70. - PubMed
    1. Agrawal S, Zaritsky JJ, Fornoni A, and Smoyer WE (2018). Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14, 57–70. - PMC - PubMed